jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2020-12-3-90-93jofin-1083Research ArticleКлинический случайClinical CaseТоцилизумаб в лечении системной воспалительной реакции у пациента с COVID-19 (клинический случай)tocilizumab in the treatment of systemic inflammatory response in a patient with CoVID-19 (clinical case)АвдошинаД. Д.AvdoshinaD. D.

Авдошина Дарья Дмитриевна – врач-инфекционист

Санкт-Петербург; тел.: 8(812)409-79-00 

Saint-Petersburg

darja_mikhailovich@mail.ruДьячковА. Г.DyachkovA. G.

Дьячков Андрей Георгиевич – заведующий отделением, ассистент кафедры инфекционных болезней и эпидемиологии

Санкт-Петербург; тел.: 8(812)409-79-62 

Saint-Petersburg

cd4@inbox.ruГусевД. А.GusevD. A.

Гусев Денис Александрович – главный врач, профессор кафедры инфекционных болезней и эпидемиологии, д.м.н., профессор

Saint-Petersburg

gusevden-70@mail.ruКлиническая инфекционная больница им. С.П. БоткинаРоссияClinical Infectious Hospital named after S.P. BotkinRussian FederationКлиническая инфекционная больница им. С.П. Боткина; Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. ПавловаРоссияClinical Infectious Hospital named after S.P. Botkin; First Saint-Petersburg State Medical University named after аcademician I.P. PavlovRussian Federation2020020820201239093Copyright © Авдошина Д.Д., Дьячков А.Г., Гусев Д.А., 20202020Авдошина Д.Д., Дьячков А.Г., Гусев Д.А.Avdoshina D.D., Dyachkov A.G., Gusev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/1083

Совершенствование подходов к лечению новой коронавирусной инфекции (COVID-19) открывает возможности использования ранее известных групп препаратов, демонстрирующих свою эффективность в патогенетической терапии данного заболевания. В Клинической инфекционной больнице им. С.П. Боткина накоплен клинический опыт в области лечения COVID-19. На примере представленного случая демонстрируется своевременность назначения и эффективность антицитокиновой терапии при COVID-19, возможности использования рекомбинантного гуманизированного моноклонального антитела к человеческому рецептору интерлейкина-6 (ИЛ-6) (МНН-тоцилизумаб).

Improving the approaches to treating COVID-19 infection opens up the possibility for using previously known groups of drugs that demonstrate their effectiveness in the pathogenetic treatment of this disease. Significant clinical experience in the field of treatment of COVID-19 have been accumulated in Clinical Infectious Diseases Hospital named after S.P. Botkin, Saint-Petersburg, Russia. The case study demonstrates the timeliness and effectiveness of anticytokine therapy with COVID-19, the possibility of using a recombinant humanized monoclonal antibody to the human receptor for interleukin-6 (IL-6) (tocilizumab).

COVID-19SARS-CoV-2острый респираторный дистресс-синдромдыхательная недостаточностьтоцилизумабCOVID-19SARS-CoV2acute respiratory distress syndromerespiratory failuretocilizumabReferencesCDC. 2019 Novel Coronavirus, Wuhan, China. Centers for Disease Control and Prevention. 2020 Jan 26; Accessed: March 25, 2020.CDC. 2019 Novel Coronavirus, Wuhan, China. Centers for Disease Control and Prevention.. 2020 Jan 26; Accessed: March 25, 2020.McCreary E.K., Pogue JM. COVID-19 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases (OFID). 2020 Mar; 23.McCreary E.K., Pogue JM. COVID-19 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases (OFID). 2020 Mar; 23.Alhazzani W., Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019. COVID-19. Critical Care Medicine. 2020 Mar.Alhazzani W., Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019. COVID-19. Critical Care Medicine. 2020 Mar.Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Apr; 13.Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Apr; 13.Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy. 2020 Apr; 7.Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy. 2020 Apr; 7.Цинзерлинг, В.А. Вопросы патоморфогенеза новой коронавирусной инфекции (COVID-19) / В.А. Цинзерлинг [и др.] // Журнал инфектологии. – 2020. –Т.12, № 2. – С. 5–11.Cinzerling V. A. Voprosy patomorfogeneza novoj koronavirusnoj infekcii (COVID-19) / V.A. Cinzerling, M.A. Vashukova, M.V. Vasil’eva, A.N. Isakov i dr. // Zhurnal infektologii. – 2020. –V.12, №2 – S.5-11Bhimraj A. Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 2020 Apr; 13Bhimraj A. Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 2020 Apr; 13FDA clears investigational new drug application for Mesoblast to use remestemcel-L in patients with acute respiratory distress syndrome caused by COVID-19. Mesoblast Ltd. 2020 Apr; 06.FDA clears investigational new drug application for Mesoblast to use remestemcel-L in patients with acute respiratory distress syndrome caused by COVID-19. Mesoblast Ltd. 2020 Apr; 06.First patients dosed in phase 2/3 randomized controlled trial of Mesoblast’s remestemcel-l for COVID-19 acute respiratory distress syndrome. Mesoblast Ltd. 2020 May; 6.First patients dosed in phase 2/3 randomized controlled trial of Mesoblast’s remestemcel-l for COVID-19 acute respiratory distress syndrome. Mesoblast Ltd. 2020 May; 6.Genentech initiates phase III clinical trial of Actemra plus remdesivir in hospitalized patients with severe COVID-19 pneumonia. Genentech. 2020 May; 27.Genentech initiates phase III clinical trial of Actemra plus remdesivir in hospitalized patients with severe COVID-19 pneumonia. Genentech. 2020 May; 27.National Health Commission (NHC) of the People’s Republic of China. The diagnosis and treatment guide of COVID-19 pneumonia caused by new coronavirus infection 7th Edition. 2020 Mar; 3.National Health Commission (NHC) of the People’s Republic of China. The diagnosis and treatment guide of COVID-19 pneumonia caused by new coronavirus infection 7th Edition. 2020 Mar; 3.

The authors declare that there are no conflicts of interest present.